<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pneumococcal conjugate vaccine (13-valent) (PCV13): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pneumococcal conjugate vaccine (13-valent) (PCV13): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pneumococcal conjugate vaccine (13-valent) (PCV13): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="15567" href="/d/html/15567.html" rel="external">see "Pneumococcal conjugate vaccine (13-valent) (PCV13): Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="90343" href="/d/html/90343.html" rel="external">see "Pneumococcal conjugate vaccine (13-valent) (PCV13): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9926715"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Prevnar 13</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914131"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Prevnar 13</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F10010046"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Bacterial)</li></ul></div>
<div class="block doa drugH1Div" id="F10010070"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f494398e-6892-4105-93a3-415a509feae1">Pneumococcal disease prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal disease prevention: IM:</b> 0.5 mL as a single dose. <b>Note: </b>Current CDC/ACIP pneumococcal vaccination guidelines recommend alternate pneumococcal conjugate vaccine options; see PCV15 and PCV20 monographs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37669242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37669242'])">Ref</a></span>). For additional guidance, the CDC recommends using the <i>PneumoRecs VaxAdvisor</i> (mobile app or web version: <a href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fagegroup.html&amp;token=S7NJDVC075c2ynIRAXnAPvQ1hfzYoEzrZ6Csny1KNFSbioH1EnyyHwxKKgy6EV9RIAIo5zF9QhQU%2Bch6fnIklA%3D%3D&amp;TOPIC_ID=9906" target="_blank">https://www2a.cdc.gov/vaccines/m/pneumo/agegroup.html</a>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Canadian recommendations:</b> The Canadian National Advisory Committee on Immunization (NACI) provides different recommendations as compared to the CDC; see NACI recommendations for details.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990354"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doha drugH1Div" id="F50987727"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doe drugH1Div" id="F10010071"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Pneumococcal disease prevention:</b>
<b>IM:</b> 0.5 mL as a single dose.<b> Note: </b>Current CDC/ACIP pneumococcal vaccination guidelines recommend alternate pneumococcal conjugate vaccine options; see PCV15 and PCV20 monographs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37669242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37669242'])">Ref</a></span>). For additional guidance, the CDC recommends using the <i>PneumoRecs VaxAdvisor</i> (mobile app or web version: <a href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fagegroup.html&amp;token=S7NJDVC075c2ynIRAXnAPvQ1hfzYoEzrZ6Csny1KNFSbioH1EnyyHwxKKgy6EV9RIAIo5zF9QhQU%2Bch6fnIklA%3D%3D&amp;TOPIC_ID=9906" target="_blank">https://www2a.cdc.gov/vaccines/m/pneumo/agegroup.html</a>).</p></div>
<div class="block dop drugH1Div" id="F10010068"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15567" href="/d/html/15567.html" rel="external">see "Pneumococcal conjugate vaccine (13-valent) (PCV13): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage Guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>According to the Advisory Committee on Immunization Practices (ACIP), doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Although pneumococcal conjugate vaccine 13-valent (PCV13) is FDA approved, ACIP recommends use of pneumococcal conjugate vaccine 15-valent (PCV15) or pneumococcal conjugate vaccine 20-valent (PCV20). If only PCV13 is available when a patient is due for a pneumococcal conjugate vaccine, PCV13 may be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37768876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37768876'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants should be vaccinated according to their chronological age from birth.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 weeks and Children ≤15 months: IM: 0.5 mL per dose for a total of 4 doses administered at 2, 4, 6, and 12 through 15 months of age. The first dose may be administered as young as 6 weeks of age.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Canadian recommendations: </i>Healthy infants: IM: 0.5 mL per dose. Routine immunization may be provided as a 4-dose schedule at 2, 4, 6, and 12 to 15 months of age, or as a 3-dose schedule at 2, 4, and 12 months of age. For infants at high risk of invasive pneumococcal disease due to an underlying medical condition, the 4-dose schedule should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Although pneumococcal conjugate vaccine 13-valent (PCV13) is FDA approved, ACIP recommends use of pneumococcal conjugate vaccine 15-valent (PCV15) or pneumococcal conjugate vaccine 20-valent (PCV20). If only PCV13 is available when a patient is due for a pneumococcal conjugate vaccine, PCV13 may be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37768876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37768876'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients initiating new vaccine series:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants 7 to &lt;12 months: IM: 0.5 mL per dose for a total of 3 doses; administer the second dose ≥4 weeks after the first; administer the third dose ≥8 weeks after the second dose and after 1 year of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;2 years: IM: 0.5 mL per dose for 2 doses administered ≥8 weeks apart (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years: <b></b></p>
<p style="text-indent:-2em;margin-left:8em;">Patients <b>without</b> any conditions that increase the risk for pneumococcal disease (ie, healthy children): IM: 0.5 mL as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients <b>with </b>conditions that increase the risk for pneumococcal disease: IM: 0.5 mL per dose for 2 doses administered ≥8 weeks apart: <b>Note: </b>If pneumococcal polysaccharide vaccine 23-valent (PPSV23) was previously administered, initiate pneumococcal conjugate vaccination ≥8 weeks after PPSV23 dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Patients with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak: IM: 0.5 mL as a single dose (even if PCV7 was previously administered). <b>Note: </b>If PPSV23 was previously administered, initiate pneumococcal conjugate vaccination ≥8 weeks after PPSV23 dose. Although FDA approved for a single catch-up dose in healthy patients 6 to 17 years of age, catch-up vaccination is not currently recommended for this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients who previously received an incomplete series with another pneumococcal conjugate vaccine (eg, PCV13)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months and Children &lt;2 years: IM: 0.5 mL per dose for a total of 1 to 3 additional doses; refer to current ACIP recommendations for specific scheduling and timing of doses based on patient age and previous doses received (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36107786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36107786'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Patients <b>without</b> any conditions that increase the risk for pneumococcal disease (ie, healthy children):</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to &lt;5 years: IM: 0.5 mL for a single dose administered ≥8 weeks after most recent pneumococcal conjugate vaccine dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥5 years: No additional doses recommended.</p>
<p style="text-indent:-2em;margin-left:8em;">Patients <b>with </b>conditions that increase the risk for pneumococcal disease: Children 2 to &lt;6 years: IM: 0.5 mL per dose for 1 to 2 additional doses; refer to current ACIP recommendations for specific scheduling and timing of doses based on previous number of doses received.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153888"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153889"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F10010061"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (5% to 56%), vomiting (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (5% to 31%), pain at injection site (36% to 97%), swelling at injection site (7% to 39%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (8% to 38%), fatigue (19% to 81%), headache (16% to 81%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7% to 42%; aggravated arthralgia: 5% to 29%), decreased range of motion (arm: 11% to 75%), myalgia (18% to 82%; aggravated myalgia: 9% to 56%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Miscellaneous: Fever (≤7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Erythema multiforme</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Gupta 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including dermatitis, injection-site pruritus, lymphadenopathy, and urticaria at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypertonia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, cyanosis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Polyserositis (pleura and pericardium) (Tawfik 2017)</p></div>
<div class="block coi drugH1Div" id="F10010058"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe allergic reaction (eg, anaphylaxis) to pneumococcal vaccine, any component of the formulation, or any diphtheria toxoid-containing vaccine</p></div>
<div class="block war drugH1Div" id="F10010059"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis, tendinitis) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Asplenia: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children ≥24 months of age with asplenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic illness: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children ≥24 months of age with chronic illness (CDC/ACIP [Nuorti 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children ≥24 months with HIV infection (CDC/ACIP [Nuorti 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pneumococcal infections: Not to be used to treat pneumococcal infections or to provide immunity against diphtheria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disease: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children ≥24 months with sickle cell disease (CDC/ACIP [Nuorti 2010]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pneumococcal polysaccharide vaccine (PPSV23): Receipt of PPSV23 within 1 year prior to pneumococcal conjugate vaccine (PCV13) diminishes response to PCV13 when compared to response in PPSV23 naïve individuals.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines (ACIP [Kroger 2023]; IDSA [Rubin 2014]). Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children ≥24 months who are immunocompromised (CDC/ACIP [Nuorti 2010]). Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Antibody responses were lower in older adults &gt;65 years of age compared to adults 50 to 59 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">• Premature infants: Antibody responses were lower in preterm infants (&lt;37 weeks gestational age) compared to term infants (≥37 weeks gestational age). Apnea following IM vaccination has been observed in some preterm infants; consider clinical status implications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878771"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Febrile seizures have been reported; CDC reports indicate that young children appear to be at increased risk of febrile seizures when given the pneumococcal conjugate vaccine (PCV13) at the same time as the inactivated influenza virus vaccine (TIV); the risk appears to be greatest from ages 12 to 23 months. Because febrile seizures are typically benign and occur in 2% to 5% of all young children, the ACIP does not recommend a delay in administration of either vaccine or altering the vaccine schedule in any manner due to the potential risk of infection. </p></div>
<div class="block foc drugH1Div" id="F10010079"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">Prevnar 13: 2 mcg of each capsular saccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4 mcg of serotype 6B [bound to diphtheria CRM<sub>197</sub> protein ~34 mcg] per 0.5 mL (0.5 mL) [contains polysorbate 80, and yeast]</p></div>
<div class="block geq drugH1Div" id="F10010044"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F10010076"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Shake well prior to use. Do not use if a homogenous white suspension does not form. Administer IM in the deltoid muscle. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not inject IV or SUBQ; avoid intradermal route. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, adolescents and adults should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614450"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM: Shake vial well before withdrawing the dose; administer IM into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults; not for IV or SUBQ administration. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block meg drugH1Div" id="F25734133"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fpcv.pdf&amp;token=zJIVwBkqWiLAAtIOP%2Bk5yXi0WEQ3KUIC%2Bb0LMW8uSqaZsYCW4XKCCMfR541gzY75vKBp1sre6mOrt4efee9SGg%3D%3D&amp;TOPIC_ID=9906" target="_blank">h<span style="text-decoration: underline">https://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv.pdf</span></a>.</p></div>
<div class="block use drugH1Div" id="F10010055"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal disease prevention:</b></p>
<ul>
<li>
<p style="text-indent:0em;">Active immunization of infants ≥6 weeks of age, children, adolescents, and adults for prevention of invasive disease caused by <i>Streptococcus pneumoniae </i>serotypes contained in the vaccine</p></li>
<li>
<p style="text-indent:0em;">Active immunization of infants ≥6 weeks of age and children &lt;6 years of age for the prevention of otitis media caused by <i>S. pneumoniae </i>serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F</p></li>
<li>
<p style="text-indent:0em;">Active immunization of adolescents ≥18 years of age and adults for the prevention of pneumonia caused by<i> S. pneumoniae</i> serotypes contained in the vaccine</p></li></ul>
<p style="text-indent:-2em;margin-left:2em;">
<b>Advisory Committee on Immunization Practices recommendations:</b></p>
<p style="text-indent:-2em;margin-left:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends routine pneumococcal vaccination for the following persons (CDC/ACIP [Kobayashi 2015]; CDC/ACIP [Kobayashi 2023]; CDC/ACIP [Nuorti 2010]):</p>
<ul>
<li>
<p style="text-indent:0em;">All infants and children 2 to 59 months of age</p></li>
<li>
<p style="text-indent:0em;">Children 60 to 71 months of age with underlying medical conditions including immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants; children with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction; children with immunocompromising conditions including congenital immunodeficiency (includes B- or T-cell deficiency, complement deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)</p></li>
<li>
<p style="text-indent:0em;">Children ≥6 years of age and Adolescents ≤18 years of age (CDC/ACIP 2013): The ACIP also recommends routine vaccination for persons with the following underlying medical conditions: Immunocompetent persons with cerebrospinal fluid leaks or cochlear implants; persons with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia; persons with immunocompromising conditions including congenital or acquired immunodeficiency (includes B- or T-cell deficiency, complement deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)</p></li></ul>
<p style="text-indent:0em;">
<b>Note:</b> Pneumococcal conjugate vaccines that are now recommended in adults include 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) (CDC/ACIP [Kobayashi 2023]).</p></div>
<div class="block mst drugH1Div" id="F10010021"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13, PCV13) may be confused with Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumovax 23), Pneumococcal 15-Valent Conjugate Vaccine (Vaxneuvance, PCV15), and Pneumococcal 20-Valent Conjugate Vaccine (Prevnar 20, PCV20).</p>
<p style="text-indent:-2em;margin-left:4em;">PCV13 (pneumococcal 13-valent conjugate vaccine) may be confused with PPSV23 (pneumococcal 23-valent polysaccharide vaccine), PCV15 (pneumococcal 15-valent conjugate vaccine) and PCV20 (pneumococcal 20-valent conjugate vaccine).</p>
<p style="text-indent:-2em;margin-left:4em;">Prevnar 13 (pneumococcal 13-valent conjugate vaccine) may be confused with Prevnar 20 (pneumococcal 20-valent conjugate vaccine).</p>
<p style="text-indent:-2em;margin-left:4em;">PCV (pneumococcal conjugate vaccine) may be confused with MCV (meningococcal ACYW conjugate vaccine, MCV4 is the correct abbreviation).</p>
<p style="text-indent:-2em;margin-left:4em;">PCV (pneumococcal conjugate vaccine) may be confused with PPD (purified protein derivative tuberculin test).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299890"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F10073253"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Inactivated): Pneumococcal Conjugate Vaccine (13-Valent) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meningococcal (Groups A / C / Y and W-135) Conjugate Vaccine: May diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Management: Administer MenACYW-D (Menactra brand) vaccine at least 4 weeks after the final dose of the PCV13 vaccine series in patients with anatomic asplenia or functional asplenia. For details and recommendations for children under 2 years, see full monograph.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Polysaccharide Vaccine (23-Valent): May diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Management: Administer PCV13 prior to administration of PPSV23. Immunocompetent patient with comorbidities: age 24 months to 71 months, separate by 8 weeks; age 65 years or older, separate by 1 year. Immunocompromised patient over age 24 months, separate by 8 weeks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Pneumococcal Vaccines. Management: Vaccination with inactivated vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during therapy, or for 6 weeks after completion of therapy. See full mono for recommendations for number, order, and timing of vaccines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F10010057"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Antibodies generated following PCV vaccination of pregnant patients can be detected in cord blood (CDC/ACIP [Kobayashi 2023]; Weinberg 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Nonlive bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2023]).</p>
<p style="text-indent:0em;margin-top:2em;">Although specific recommendations for vaccination of pregnant patients are not available (CDC/ACIP [Kobayashi 2023]), pneumococcal vaccines may be administered during pregnancy in persons at increased risk of severe disease due to underlying medical conditions (ACOG 2018; ACOG 2022).</p></div>
<div class="block brc drugH1Div" id="F11566484"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if the components of this vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed following immunization should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Nonlive vaccines have not been shown to affect the safety of the breastfed infant or mother. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2023]).</p></div>
<div class="block mop drugH1Div" id="F28625255"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F10010066"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes active immunization against invasive disease caused by <i>S. pneumoniae</i> capsular serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all which are individually conjugated to CRM197 protein</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390245"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13 multidose</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(PA)</span> <span class="country">Panama</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Prevnar 13</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Prevnar 13</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Prevenar 13</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20498180">
<a name="20498180"></a>American Academy of Pediatrics Committee on Infectious Diseases, "Recommendations for the Prevention of <i>Streptococcus pneumoniae</i> Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)," <i>Pediatrics</i>, 2010, 126(1):186-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/20498180/pubmed" id="20498180" target="_blank">20498180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794683">
<a name="29794683"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 741: Maternal Immunization. <i>Obstet Gynecol</i>. 2018;131(6):e214-e217. doi:10.1097/AOG.0000000000002662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/29794683/pubmed" id="29794683" target="_blank">29794683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). Maternal Immunization Practice Advisory. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/10/maternal-immunization. Updated October 2022. Accessed December 13, 2022.</div>
</li>
<li>
<div class="reference">
                  Bennett NM. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(25):521-528.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23803961">
<a name="23803961"></a>Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(25):521-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/23803961/pubmed" id="23803961" target="_blank">23803961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303‐306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37768876">
<a name="37768876"></a>Farrar JL, Gierke R, Andrejko, et al. ACIP updates: recommendations for use of 20-valent pneumococcal conjugate vaccine in children - United States, 2023. <i>MMWR Morb Mortal Wkly Rep</i>. 2023;72(39):1072. doi:10.15585/mmwr.mm7239a5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/37768876/pubmed" id="37768876" target="_blank">37768876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102‐103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26915880">
<a name="26915880"></a>Gupta S, Brennan DC. Pneumococcal 13-valent conjugate vaccine (Prevnar 13)-associated immune thrombocytopenic purpura in a renal transplant recipient: a case report. <i>Transplant Proc</i>. 2016;48(1):262-264. doi:10.1016/j.transproceed.2015.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/26915880/pubmed" id="26915880" target="_blank">26915880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182599">
<a name="28182599"></a>Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/28182599/pubmed" id="28182599" target="_blank">28182599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26334788">
<a name="26334788"></a>Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(34):944-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/26334788/pubmed" id="26334788" target="_blank">26334788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36107786">
<a name="36107786"></a>Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. <i>MMWR Morb Mortal Wkly Rep</i>. 2022b;71(37):1174-1181. doi:10.15585/mmwr.mm7137a3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/36107786/pubmed" id="36107786" target="_blank">36107786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37669242">
<a name="37669242"></a>Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. <i>MMWR Recomm Rep.</i> 2023;72(3):1-39. doi:10.15585/mmwr.rr7203a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/37669242/pubmed" id="37669242" target="_blank">37669242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed June 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31751323">
<a name="31751323"></a>Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices [published correction appears in <i>MMWR Morb Mortal Wkly Rep</i>. 2020;68(5152):1195]. <i>MMWR Morb Mortal Wkly Rep</i>. 2019;68(46):1069-1075. doi: 10.15585/mmwr.mm6846a5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/31751323/pubmed" id="31751323" target="_blank">31751323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.1">
<a name="NACI.1"></a>National Advisory Committee on Immunizations. Pneumococcal vaccine. Canadian immunization guide, 2012-2014. Available at: <a href="http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-pneu-eng.php#ru" target="_blank">http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-pneu-eng.php#ru</a>. Accessed August 31, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.2">
<a name="NACI.2"></a>National Advisory Committee on Immunization (NACI). Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation. Available at: <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/update-use-of-13-valent-pneumococcal-conjugate-vaccine-pneu-c-13-in-addition-to-23-valent-pneumococcal-polysaccharide-vaccine-pneu-p-23-immunocompetent-adults-65-years-and-older-interim-recommendation.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/healthy-living/update-use-of-13-valent-pneumococcal-conjugate-vaccine-pneu-c-13-in-addition-to-23-valent-pneumococcal-polysaccharide-vaccine-pneu-p-23-immunocompetent-adults-65-years-and-older-interim-recommendation.html</a>. Published October 17, 2016. Accessed January 17, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21293327">
<a name="21293327"></a>National Center for Immunization and Respiratory Diseases (NCIRD). General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Recomm Rep</i>. 2011;60:993]. <i>MMWR Recomm Rep</i>. 2011;60(2):1-64. 4GODalways<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/21293327/pubmed" id="21293327" target="_blank">21293327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21150868">
<a name="21150868"></a>Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2010;59(RR-11):1-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/21150868/pubmed" id="21150868" target="_blank">21150868</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Prevnar 13 (pneumococcal conjugate vaccine [13-valent]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; July 2019.</div>
</li>
<li>
<div class="reference">
                  Prevnar 13 (pneumococcal conjugate vaccine [13-valent]) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC, Licensee; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12890842">
<a name="12890842"></a>Reefhuis J, Honein MA, Whitney CG, et al, “Risk of Bacterial Meningitis in Children With Cochlear Implants,” <i>N Engl J Med</i>, 2003, 349:435-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/12890842/pubmed" id="12890842" target="_blank">12890842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28526059">
<a name="28526059"></a>Tawfik P, Gertner E, McEvoy CE. Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report. <i>J Med Case Rep</i>. 2017;11(1):142. doi:10.1186/s13256-017-1305-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/28526059/pubmed" id="28526059" target="_blank">28526059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33915104">
<a name="33915104"></a>Weinberg A, Muresan P, Laimon L, et al; NICHD P1091 study team. Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial.<i> Lancet HIV</i>. 2021;8(7):e408-e419. doi:10.1016/S2352-3018(20)30339-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-pcv13-drug-information/abstract-text/33915104/pubmed" id="33915104" target="_blank">33915104</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 9906 Version 229.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
